CD22 Antibody (HD239): sc-18909
- CD22 Antibody (HD239) is a mouse monoclonal IgG2b κ, cited in 2 publications, provided at 200 µg/ml
- recommended for detection of CD22 of human origin by IP, IF and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- m-IgG2b BP-HRP is the preferred secondary detection reagent for CD22 Antibody (HD239). This reagent is now offered in a bundle with CD22 Antibody (HD239) (see ordering information below).
QUICK LINKS
SEE ALSO...
CD22 Antibody (HD239) is a mouse monoclonal IgG2b antibody that detects CD22 in human samples through immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD22 is a critical regulator of B cell signaling and plays a vital role in the immune response by modulating the activation and differentiation of B lymphocytes. CD22 (HD239) antibody targets a protein primarily located on the surface of B cells, where CD22 functions as a cell adhesion molecule, facilitating interactions between B cells and other immune cells. CD22 expression on mature B cells is essential for maintaining immune tolerance and preventing autoimmunity, as CD22 helps regulate the strength and duration of B cell receptor signaling. Additionally, CD22 undergoes alternative splicing, resulting in two isoforms, CD22α and CD22β, with CD22β being the predominant form. CD22′s ability to form heterodimers with its isoforms enhances functional diversity, allowing for fine-tuning of B cell responses. Anti-CD22 antibody (HD239) is an invaluable tool for researchers studying B cell biology and related diseases, including acute lymphocytic leukemia, where cytoplasmic CD22 serves as a significant marker.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD22 Antibody (HD239) References:
- Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies. | Zheng, S., et al. 2022. Blood Cancer Discov. 3: 103-115. PMID: 35015683
- CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. | Bueno, C., et al. 2022. Blood. 140: 38-44. PMID: 35421218
- Targeting CD22 on memory B cells to induce tolerance to peanut allergens. | Hardy, LC., et al. 2022. J Allergy Clin Immunol. 150: 1476-1485.e4. PMID: 35839842
- Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR. | Kokalaki, E., et al. 2023. Mol Ther. 31: 2089-2104. PMID: 36945773
- Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells. | Tian, X., et al. 2023. Cent Eur J Immunol. 48: 1-13. PMID: 37206593
- CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity. | Jess, J., et al. 2023. J Immunother Cancer. 11: PMID: 37295816
- CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma. | Liu, T., et al. 2023. J Transl Med. 21: 710. PMID: 37817249
- ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies. | Zammarchi, F., et al. 2024. Mol Cancer Ther. 23: 520-531. PMID: 38324336
- Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22. | McComb, S., et al. 2024. Mol Ther Oncol. 32: 200775. PMID: 38596311
- CD22 CAR T-cell therapy: new hope for patients with large B-cell lymphoma. | Schubert, ML. and Dreger, P. 2024. Lancet. 404: 314-315. PMID: 38996464
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD22 Antibody (HD239) | sc-18909 | 200 µg/ml | $316.00 | |||
CD22 Antibody (HD239): m-IgG2b BP-HRP Bundle | sc-548429 | 200 µg Ab; 10 µg BP | $354.00 | |||
CD22 Antibody (HD239) FITC | sc-18909 FITC | 200 µg/ml | $330.00 | |||
CD22 Antibody (HD239) PE | sc-18909 PE | 200 µg/ml | $343.00 |